Qaasid News

Download Our App

Category: 3. Business

  • Apollo to Announce Fourth Quarter and Full Year 2025 Financial Results on February 9, 2026Apollo Global Management

    Apollo to Announce Fourth Quarter and Full Year 2025 Financial Results on February 9, 2026Apollo Global Management

    NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) plans to release financial results for the fourth quarter and full year 2025 on Monday, February 9, 2026, before the opening of trading on the New York Stock Exchange. Management will review Apollo’s financial results at 8:30 am ET via public webcast available on Apollo’s Investor Relations website at ir.apollo.com. A replay will be available one hour after the event.

    Apollo distributes its earnings releases via its website and email lists. Those interested in receiving firm updates by email can sign up for them here.

    About Apollo

    Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, our investing expertise across our fully integrated platform has served the financial return needs of our clients and provided businesses with innovative capital solutions for growth. Through Athene, our retirement services business, we specialize in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Our patient, creative, and knowledgeable approach to investing aligns our clients, businesses we invest in, our employees, and the communities we impact, to expand opportunity and achieve positive outcomes. As of September 30, 2025, Apollo had approximately $908 billion of assets under management. To learn more, please visit www.apollo.com.

    Contacts

    Noah Gunn
    Global Head of Investor Relations
    Apollo Global Management, Inc.
    (212) 822-0540
    IR@apollo.com

    Joanna Rose
    Global Head of Corporate Communications
    Apollo Global Management, Inc.
    (212) 822-0491
    Communications@apollo.com

    Continue Reading

  • Blackstone Energy Transition Partners Announces Acquisition of Alliance Technical Group

    Blackstone Energy Transition Partners Announces Acquisition of Alliance Technical Group

    New York, NY – January 6, 2026 – Blackstone (NYSE: BX) announced today that funds affiliated with Blackstone Energy Transition Partners and other Blackstone funds (“Blackstone”) have acquired Alliance Technical Group (“ATG”), a leading provider of environmental testing, monitoring, and compliance services.
     
    Founded in 2000 and headquartered in Alabama, ATG has grown into one of the largest full-service environmental compliance providers in North America, with more than 2,200 employees located in 60-plus offices and labs across the U.S. and Canada. ATG delivers a comprehensive suite of solutions – including source and lab testing, continuous emission monitoring systems (CEMS), and leak detection and repair, among others – to help businesses maintain regulatory compliance and safety, while driving efficiency through ATG’s data-driven insights.
     
    Chris LeMay, Chief Executive Officer at Alliance Technical Group, said: “Blackstone’s investment is a testament to our strong organic and strategic growth as a trusted market leader in the testing, inspection and compliance sector. With our partners at Blackstone, we look forward to continuing to scale and support our customers in navigating a complex, evolving regulatory landscape.”
     
    Darius Sepassi, Senior Managing Director, and Mark Henle, Managing Director, at Blackstone, said: “Alliance is a clear market leader in emissions testing and monitoring, providing mission-critical services that directly support customers’ compliance and operational performance. Chris and the ATG management team have built a diversified platform with a strong reputation for technical quality and reliability. Together, we are excited to leverage Blackstone’s scale and resources to help support ATG’s continued growth, serving its existing and new customers across the power, energy and industrial sectors.”
     
    David Foley, Global Head of Blackstone Energy Transition Partners, added: “Our investment strategy focuses on identifying leading businesses that we believe are positioned to disproportionately benefit from the growing demand for electricity and the broader energy transition. We are excited to back Alliance, which plays a critical role in helping energy and industrial facilities operate safely, efficiently, and in compliance with environmental regulations.”
     
    Alliance Technical Group represents the latest in a number of recent transactions Blackstone Energy Transition Partners has announced behind its high-conviction investment themes in electricity demand growth and the ongoing energy transition, including Maclean Power Systems, Wolf Summit Energy, Hill Top Energy Center, Shermco, Enverus, Lancium, Westwood, and others.
     
    Terms of the transaction were not disclosed. Harris Williams and RBC acted as financial advisor and Kirkland & Ellis acted as a legal advisor to Blackstone. Piper Sandler served as financial advisor and Jones Day served as a legal advisor to Alliance.
     
    About Blackstone Energy Transition Partners
    Blackstone Energy Transition Partners is Blackstone’s strategy for control-oriented equity investments in energy-related businesses, a leading energy investor with a successful long-term record, having committed over $27 billion of equity globally across a broad range of sectors within the energy industry. Our investment philosophy is based on backing exceptional management teams with flexible capital to provide solutions that help energy companies grow and improve performance, thereby delivering more reliable, affordable and cleaner energy to meet the growing needs of the global community. In the process, we build stronger, larger scale enterprises, create jobs and generate lasting value for our investors, employees and all stakeholders. Further information is available at https://www.blackstone.com/our-businesses/blackstone-energy-transition-partners/.
     
    About Blackstone
    Blackstone is the world’s largest alternative asset manager. Blackstone seeks to deliver compelling returns for institutional and individual investors by strengthening the companies in which the firm invests. Blackstone’s over $1.2 trillion in assets under management include global investment strategies focused on real estate, private equity, credit, infrastructure, life sciences, growth equity, secondaries and hedge funds. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, X (Twitter), and Instagram.
     
    About Alliance Technical Group
    Alliance Technical Group, LLC (Alliance), headquartered in Decatur, AL, is the premier environmental services and solutions company dedicated to helping facilities achieve their environmental goals and navigate regulatory changes through the company’s On-site Testing and Monitoring, Environmental Compliance, and Laboratory Testing and Analysis offerings. Driven by innovation, committed to service, and focused on client success, Alliance delivers on the promise of responsiveness, reliability, and results. Learn more about how Alliance helps clients maximize their environmental opportunities: www.alliancetg.com
     
    Media Contacts
     
    Blackstone
    Jennifer Heath
    [email protected]
     
    Alliance Technical Group
    Jarred Smith
    [email protected]


    Continue Reading

  • Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

    SPRING HOUSE, Pa., (January 6, 2026) – Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic lupus erythematosus (SLE) and the initiation of a Phase 3 program. The JASMINE study met the primary endpoint (percentage of patients achieving Systemic Lupus Erythematosus Responder Index [SRI-4]a composite response at Week 24 with statistical significance compared with placebo), and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for steroid sparing. Nipocalimab had a safety and tolerability profile consistent with previous Phase 2 studies, with no new safety signals identified.

    These data represent the first positive results of an investigational FcRn blocker treatment in this chronic, debilitating autoantibody-driven disease that impacts an estimated 3 to 5 million people worldwide, and 450,000 in the U.S.1,2 , Chronic symptoms of SLE include severe fatigue, joint pain and swelling, and rashes, including a hallmark butterfly-shaped facial rash.3

    JASMINE is a 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of nipocalimab in 228 adult participants with active SLE and the first positive study of an FcRn blocker for the treatment of active SLE.4

    “Systemic lupus erythematosus or SLE is a serious autoantibody-driven disease that can impact multiple organ systems, significantly reducing health-related quality of life for millions of people,” said Leonard L. Dragone, M.D., Ph.D., Disease Area Leader, Autoantibody and Rheumatology, Johnson & Johnson Innovative Medicine. “Many people living with SLE also face complications associated with long-term steroid use, underscoring the limitations of current treatment approaches and the critical need for immunoselective therapies that are safe, tolerable, and capable of reducing disease activity, while preserving immune function.”

    Full results from the JASMINE study will be presented at a future medical congress.

    Editor’s note:
    a. The SLE Responder Index 4 (SRI-4) is a composite measure used to assess treatment response in patients with SLE during clinical studies. It comprises criteria from three different internationally validated indices, SELENA-SLE Disease Activity Index (SELENA-SLEDAI), Physician Global Assessment (PGA) and the British Isles Lupus Assessment Group (BILAG) 2004.

    ABOUT JASMINE
    JASMINE (NCT04882878) is a 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of nipocalimab in 228 adult participants with active SLE and the first positive study of an FcRn blocker for the treatment of active SLE.4

    ABOUT SYSTEMIC LUPUS ERYTHEMATOSUS
    Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that occurs when the body’s immune system mistakenly attacks its own healthy tissues. This can lead to inflammation and damage in many parts of the body, including the skin, joints, heart, lungs, kidneys, and brain. SLE affects nine times more women than men, often striking initially between the ages of 15-44.7 In addition to systemic organ damage, other complications of SLE can include end-stage renal failure, scarring cutaneous lesions, neurological damage, and various forms of cardiovascular disease.5 People living with SLE often face reduced health-related quality of life, due to severe fatigue, mood disturbances, joint pain and swelling, and rashes, including the hallmark butterfly-shaped facial rash, as well as complications of long-term glucocorticoid use.3 Severe fatigue is the most widely reported and debilitating symptom of SLE, affecting up to 80% of people with SLE. SLE is the most common form of lupus, affecting 3 to 5 million people worldwide, approximately 70% of lupus cases.1,7 It is estimated that 450,000 people in the United States are affected by SLE.2

    ABOUT NIPOCALIMAB
    Nipocalimab is an investigational monoclonal antibody, designed to bind with high affinity to block FcRn and reduce levels of circulating immunoglobulin G (IgG) antibodies potentially without additional detectable effects on other adaptive and innate immune functions. This includes autoantibodies and alloantibodies that underlie multiple conditions across three key segments in the autoantibody space including Rare Autoantibody diseases, Maternal Fetal diseases mediated by maternal alloantibodies and autoantibody-driven Rheumatic diseases.8,9,10,11,12,13,14,15,16 Blockade of IgG binding to FcRn in the placenta is also believed to limit transplacental transfer of maternal alloantibodies to the fetus.17,18

    The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted several key designations to nipocalimab including:  

    • EU EMA Orphan medicinal product designation for hemolytic disease of the fetus and newborn (HDFN) in October 2019 and fetal and neonatal alloimmune thrombocytopenia (FNAIT) in April 2025
    • U.S. FDA Fast Track designation in HDFN and warm autoimmune hemolytic anemia (wAIHA) in July 2019, gMG in December 2021, FNAIT in March 2024 and Sjögren’s disease (SjD) in March 2025
    • U.S. FDA Orphan drug status for wAIHA in December 2019, HDFN in June 2020, gMG in February 2021, chronic inflammatory demyelinating polyneuropathy (CIDP) in October 2021 and FNAIT in December 2023
    • U.S. FDA Breakthrough Therapy designation for HDFN in February 2024 and for Sjögren’s disease in November 2024
    • U.S. FDA granted Priority Review in generalized myasthenia gravis in Q4 2024

    ABOUT JOHNSON & JOHNSON
    At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.

    Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com.

    Follow us at @JNJInnovMed.

    Janssen Research & Development, LLC, Janssen Biotech, Inc. and Janssen Global Services, LLC are Johnson & Johnson companies.

    Cautions Concerning Forward-Looking Statements
    This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of nipocalimab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

    Footnotes
    1 Tian, J., Zhang, D., Yao, X., Huang, Y., & Lu, Q. (2023). Global epidemiology of systemic lupus erythematosus: A comprehensive systematic analysis and modelling study. Annals of the Rheumatic Diseases, 82(3), 351–356. https://doi.org/10.1136/ard-2022-223035
    2 Wang, Y., Hester, L. L., Lofland, J., Rose, S., Karyekar, C.S., Kern, D.M., Blacketer, M., Davis, K., & Sheilds-Tuttle, K. (2022). Update on the prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016. BMC Research Notes, 15, 5. https://doi.org/10.1186/s13104-021-05877-1
    3 Centers for Disease Control and Prevention. (2024). Symptoms of lupus. https://www.cdc.gov/lupus/signs-symptoms/. Last accessed: January 2026.
    4 ClinicalTrials.gov Identifier: NCT04882878. Available at: https://clinicaltrials.gov/study/NCT04882878. Last accessed: January 2026.
    5 National Institute of Arthritis and Musculoskeletal and Skin Disease. (2022) Systemic Lupus Erythematosus (Lupus). https://www.niams.nih.gov/health-topics/lupus. Last accessed: January 2026.
    6 Ahn, G.E., & Ramsey-Goldman, R. (2012). Fatigue systemic lupus erythematosus. International Journal of Clinical Rheumatology, 7(2), 217–227. https://doi.org/10.2217/IJR.12.4
    7 Lupus Foundation of America. Lupus facts and statistics. https://www.lupus.org/resources/lupus-facts-and-statistics. Last accessed: January 2026.
    8 ClinicalTrials.gov. NCT03842189. Available at: https://clinicaltrials.gov/ct2/show/NCT03842189. Last accessed: January 2026.
    9 ClinicalTrials.gov Identifier: NCT05327114. Available at: https://www.clinicaltrials.gov/study/NCT05327114. Last accessed: January 2026.
    10 ClinicalTrials.gov Identifier: NCT04119050. Available at: https://clinicaltrials.gov/study/NCT04119050. Last accessed: January 2026.
    11 ClinicalTrials.gov Identifier: NCT05379634. Available at: https://clinicaltrials.gov/study/NCT05379634. Last accessed: January 2026.
    12 ClinicalTrials.gov Identifier: NCT05912517. Available at: https://www.clinicaltrials.gov/study/NCT05912517. Last accessed: January 2026.
    13 ClinicalTrials.gov Identifier: NCT04968912. Available at: https://www.clinicaltrials.gov/study/ NCT04968912. Last accessed: January 2026.
    14 ClinicalTrials.gov Identifier: NCT04882878. Available at: https://clinicaltrials.gov/study/NCT04882878. Last accessed: January 2026.
    15 ClinicalTrials.gov Identifier: NCT06449651. Available at: https://clinicaltrials.gov/study/ NCT06449651. Last accessed: January 2026.
    16 ClinicalTrials.gov Identifier: NCT06533098. Available at: https://clinicaltrials.gov/ct2/show/NCT06533098. Last accessed: January 2026.
    17 Lobato G, Soncini CS. Relationship between obstetric history and Rh(D) alloimmunization severity. Arch Gynecol Obstet. 2008 Mar;277(3):245-8. DOI: 10.1007/s00404-007-0446-x. Last accessed: January 2026.
    18 Roy S, Nanovskaya T, Patrikeeva S, et al. M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model. Am J Obstet Gynecol. 2019;220(5):498 e491-498 e499.


    Continue Reading

  • Access Denied


    Access Denied

    You don’t have permission to access “http://www.war.gov/News/Releases/Release/Article/4371320/department-of-war-establishes-new-acquisition-model-to-more-than-triple-pac-3-m/” on this server.

    Reference #18.13d91102.1767704373.448efee2

    https://errors.edgesuite.net/18.13d91102.1767704373.448efee2

    Continue Reading

  • Mitie’s Net Zero Navigator reveals risks of delaying decarbonisation – Mitie

    1. Mitie’s Net Zero Navigator reveals risks of delaying decarbonisation  Mitie
    2. Net Zero Navigator 2026  Mitie
    3. Technology – From ambition to accountability: How corporate decarbonisation is changing  Business Reporter
    4. 2026: Time to Get on the Right Boat  Business News Wales
    5. This is the worst possible time to double down on net zero  The Telegraph

    Continue Reading

  • Two new partners and six new of counsel at Arthur Cox LLP

    Two new partners and six new of counsel at Arthur Cox LLP

    We are pleased to announce the appointment of two new partners and six new of counsel across the firm in Employment, Corporate and M&A, Technology and Innovation, Real Estate, Financial Regulation and Litigation, Dispute Resolution and Investigations.

    These appointments reflect our commitment to investing in exceptional talent and strengthening the breadth of expertise across the firm. By promoting and developing our people, we can ensure that our clients benefit from innovative thinking, deep sector knowledge, and the highest standards of legal service.

    Geoff Moore, Managing Partner, commented: “These appointments demonstrate the depth of expertise within our firm and our focus on supporting clients with the highest standards of legal advice, particularly in areas of key strategic importance. Each of these individuals brings outstanding experience and insight, and I am proud to see them take on these new roles as the firm continues to grow.”

    About our new appointments:

    Sarah Faulkner, Partner, Employment

    Sarah advises on all aspects of employment law, including disciplinary investigations, contract terminations, recruitment, redundancies, settlement agreements, and discrimination complaints. She represents clients before the Workplace Relations Commission and Labour Court in disputes such as unfair dismissal, equality, transfer of undertakings, and working time. Sarah also acts for clients in employment-related civil court proceedings and advises on the employment aspects of commercial transactions and outsourcings, particularly TUPE compliance. She is a CEDR Accredited Mediator.

    Sarah McDermott, Partner, Corporate and M&A  

    Sarah advises Irish and multinational public and private companies on all aspects of corporate and commercial law. She advises on domestic and cross-border mergers and acquisitions, corporate finance transactions, corporate reorganisations, corporate governance, and commercial contracts across a range of industries and sectors.  Sarah also advises international and domestic publicly listed clients on strategic transactions such as public takeovers, capital raises, corporate restructuring, and governance matters.

    Ciara Anderson, Of Counsel, Technology and Innovation

    Ciara has particular expertise in data protection, outsourcing, digital transformation, IT contracts, freedom of information, and export control. She works with financial institutions, corporates, and technology companies on a range of complex transformation and procurement projects, including cloud outsourcings, digital transformation projects, and business-critical IT contracts. She also advises a range of clients on data protection, including in relation to complex international data transfer strategies, such as binding corporate rules (BCRs).

    Lisa Boyle, Of Counsel, Corporate and M&A

    Lisa specialises in securities law and governance for public companies with equity listings across multiple jurisdictions. As a key advisor in our PLC Advisory and Governance Group, she guides companies on compliance frameworks including market abuse regulations, shareholder engagement, and board governance to help them meet market and investor expectations. Lisa has extensive experience advising on equity capital markets transactions, including complex regulatory frameworks for initial listings and market transitions.

    Elaine Caulfield, Of Counsel, Real Estate

    Elaine advises clients on commercial real estate transactions across all sectors, including office, retail, healthcare, logistics, hospitality and PRS/BTR. She has extensive experience in portfolio and single-asset acquisitions and disposals, landlord and tenant matters and asset management.  She also regularly advises on the real estate aspects of property finance and corporate (M&A) transactions.

    Kim O’Dowd, Of Counsel, Financial Regulation

    Kim advises domestic and international clients on all aspects of financial services regulation. Her clients include banks, investment firms, payment services firms, and e-money institutions offering services such as deposit taking, lending, investment, fintech, crypto-assets, and payment services. Kim provides guidance on Irish and EU authorisation, including applications for regulatory permissions. She advises on compliance, conduct of business, regulatory capital, market abuse, AML and countering the financing of terrorism. Kim has extensive experience in advising on consumer protection matters and also advises on financial services M&A matters.

    Niamh O’Toole, Of Counsel, Corporate and M&A

    Niamh works with Irish and international clients on all aspects of corporate law and governance, with a focus on public and private mergers and acquisitions, equity capital market transactions, corporate reorganisations, joint ventures, and general corporate advisory work. Niamh advises on Irish and multi-jurisdictional transactions across a broad range of industries and has considerable experience in public corporate governance and securities advisory work for publicly listed clients.

    Zac Van Horn, Of Counsel, Litigation, Dispute Resolution and Investigations

    Zac advises on complex contractual disputes, shareholder disputes, and commercial property disputes, working with Irish and international corporates, investment funds, financial institutions, insolvency practitioners, and high-net-worth individuals. He has acted in arbitrations and in litigation matters at all levels of jurisdiction of the Irish courts. Zac is also experienced in pre-dispute risk management, negotiation, and mediation.

    Standing, left to right: Ciara Anderson, Zac Van Horn, Sarah Faulkner, Elaine Caulfield, Lisa Boyle, Geoff Moore, Kim O’Dowd.

    Sitting, left to right: Sarah McDermott, Niamh O’Toole.

    Continue Reading

  • Kyndryl announces leadership rotations and appointments

    Kyndryl announces leadership rotations and appointments

    Harsh Chugh will take on an expanded role as Global Head of Practices, Corporate Development and Administration. In this new role, he will lead Kyndryl’s Global Practices, effective immediately, and will lead Corporate Development beginning May 1. Country practices will continue to operate with the same reporting structure as they do today. Chugh will integrate the practices and corporate development agenda for future growth with a focus on leveraging the combined and holistic value the practices provide customers, while maintaining a flat structure. As Kyndryl’s Chief Operating Officer, Chugh has transformed the company through the successful transition services agreement (TSA) exit and solved tough commercial challenges. Chugh will continue to own all aspects of operations for Kyndryl.

    Farhaz Thobani will become Chief Administrative Officer, responsible for Kyndryl’s operations, real estate, quote to cash and procurement, effective immediately. As President of Kyndryl Canada, Thobani transformed Kyndryl’s Canadian business while fostering a highly engaged team. Under his leadership, the team has strengthened customer relationships, elevated Kyndryl’s brand presence and laid a robust foundation for sustained growth in Canada.

    Paul Savill will become, effective immediately, Global Practice Leader, Cyber Security and Resiliency, Network and Edge, which is a newly combined Global Practice that reflects the integrated way customers view and purchase network and security offerings. Previously, as Global Practice Leader for Network and Edge, Paul has been a senior leader at Kyndryl since it became an independent company and has transformed the Network and Edge Practice to focus on growth and innovation while building a strong, experienced team. He will bring together these two teams of experts to provide customers with a unified set of capabilities and support.

    Ivan Dopplé has decided to retire following a distinguished career at Kyndryl. After building and leading Kyndryl operations during its transition to an independent company, Dopplé has led its Digital Workplace Services (DWS) Global Practice. Dopplé has been instrumental in establishing Kyndryl’s eminence in the DWS space, driven by a deep passion for customers and keen industry insights. Dopplé has also been an advocate for the company’s culture, including his leadership as the Executive Sponsor for KIN True Ability. He will remain at Kyndryl until July to transition with his successor and work on projects focused on advancing the company’s growth.

    Michael Przytula will join Kyndryl on January 19 as Global Practice Leader, Digital Workplace. Przytula brings almost 30 years of experience leading and delivering Digital Workplace and Service Desk services for global customers at Accenture, Dell and HP. He has spent his career in this space, working across every role in the practice and brings a global perspective shaped by living and working in Australia, Asia and the United States.

    Continue Reading

  • Pursuit, Adoption of State-Level OZ Incentives on a Longer Timeline, Say Experts – Novogradac

    1. Pursuit, Adoption of State-Level OZ Incentives on a Longer Timeline, Say Experts  Novogradac
    2. Why 2026 Is a Pivotal Year for Opportunity Zones  OpportunityZones.com
    3. Opportunity Zones are about to matter again, says GTIS Partners’ head of capital markets  InvestmentNews
    4. Help clients take advantage of new opportunity zone tax advantages  Accounting Today

    Continue Reading

  • Whataburger launches new ‘Whatadeal’ menu for 2026

    Whataburger launches new ‘Whatadeal’ menu for 2026

    The menu is available for a limited time only at participating locations

    Whataburger launches new deals menu for 2026 (Copyright Whataburger)

    SAN ANTONIO – Whataburger is giving you more to love in 2026 with a new Whatadeal menu.

    You can enjoy options for as low as $3 for a limited time only at participating locations, according to a press release from the popular chain.

    The new menu includes three options, with the ability to add small fries and a small drink for $2.49.

    “We’ve always believed that good, fresh food should be easy to enjoy and easy on the wallet,” said Whataburger Senior Vice President and CMO Scott Hudler. “The Whatadeal menu is our way of giving fans more of what they love at prices that make it easy to come hungry and leave full.”

    You can get a Big Ranch Wrap for $3. Whataburger said this is its Whatachick’n Strip with fresh veggies, ranch and American cheese wrapped in a tortilla.

    For $4, you can chow down on a five-count Whatachick’n Bites. Just like it sounds, these are bite-sized crispy chicken pieces for dipping and snacking.

    The Bacon and Cheese Whataburger Jr. is available for $5. The chain said this features a 100% beef patty topped with bacon and melty cheese.

    You can learn more on Whataburger’s website.

    Read more on KSAT:

    Copyright 2026 by KSAT – All rights reserved.

    Continue Reading

  • Insights from three decades of BRCA1/2 modeling in mice

    Insights from three decades of BRCA1/2 modeling in mice

  • Capecchi, M. R. Altering the genome by homologous recombination. Science 244, 1288–1292 (1989).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Gowen, L. C., Johnson, B. L., Latour, A. M., Sulik, K. K. & Koller, B. H. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat. Genet. 12, 191–194 (1996).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Hakem, R. et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85, 1009–1023 (1996).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Liu, C. Y., Flesken-Nikitin, A., Li, S., Zeng, Y. & Lee, W. H. Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev. 10, 1835–1843 (1996).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Ludwig, T., Chapman, D. L., Papaioannou, V. E. & Efstratiadis, A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 11, 1226–1241 (1997).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Sharan, S. K. et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386, 804–810 (1997).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Suzuki, A. et al. Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev. 11, 1242–1252 (1997).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Shen, S. X. et al. A targeted disruption of the murine Brca1 gene causes γ-irradiation hypersensitivity and genetic instability. Oncogene 17, 3115–3124 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Xu, X. et al. Centrosome amplification and a defective G2–M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3, 389–395 (1999).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Connor, F. et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat. Genet. 17, 423–430 (1997).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Patel, K. J. et al. Involvement of Brca2 in DNA repair. Mol. Cell 1, 347–357 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Tutt, A. et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. 20, 4704–4716 (2001).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lomonosov, M., Anand, S., Sangrithi, M., Davies, R. & Venkitaraman, A. R. Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. Genes Dev. 17, 3017–3022 (2003).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Schlacher, K. et al. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 145, 529–542 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Schlacher, K., Wu, H. & Jasin, M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51–BRCA1/2. Cancer Cell 22, 106–116 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hatchi, E. et al. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. Mol. Cell 57, 636–647 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Shivji, M. K. K., Renaudin, X., Williams, C. H. & Venkitaraman, A. R. BRCA2 regulates transcription elongation by RNA polymerase II to prevent R-loop accumulation. Cell Rep. 22, 1031–1039 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zhang, X. et al. Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis. Nat. Commun. 8, 15908 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Patel, P. S. et al. RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors. J. Clin. Invest. 131, e140105 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Xu, X., Aprelikova, O., Moens, P., Deng, C.-X. & Furth, P. A. Impaired meiotic DNA-damage repair and lack of crossing-over during spermatogenesis in BRCA1 full-length isoform deficient mice. Development 130, 2001–2012 (2003).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Broering, T. J. et al. BRCA1 establishes DNA damage signaling and pericentric heterochromatin of the X chromosome in male meiosis. J. Cell Biol. 205, 663–675 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sharan, S. K. et al. BRCA2 deficiency in mice leads to meiotic impairment and infertility. Development 131, 131–142 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Hakem, R., de la Pompa, J. L., Elia, A., Potter, J. & Mak, T. W. Partial rescue of Brca15–6 early embryonic lethality by p53 or p21 null mutation. Nat. Genet. 16, 298–302 (1997).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Xu, X. et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat. Genet. 28, 266–271 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Cao, L. et al. ATM–Chk2–p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency. EMBO J. 25, 2167–2177 (2006).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Cao, L. et al. A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol. Cell 35, 534–541 (2009).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17, 688–695 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Bunting, S. F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243–254 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Petrucelli, N., Daly, M. B. & Pal, T. In GeneReviews (eds Adam, M. P. et al.) (University of Washington, 1998–2025).

  • Ludwig, T., Fisher, P., Ganesan, S. & Efstratiadis, A. Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes Dev. 15, 1188–1193 (2001).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Bachelier, R. et al. Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice. Oncogene 22, 528–537 (2003).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kim, S. S. et al. Hyperplasia and spontaneous tumor development in the gynecologic system in mice lacking the BRCA1-Δ11 isoform. Mol. Cell. Biol. 26, 6983–6992 (2006).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Friedman, L. S. et al. Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Res. 58, 1338–1343 (1998).

    CAS 
    PubMed 

    Google Scholar 

  • McAllister, K. A. et al. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer Res. 62, 990–994 (2002).

    CAS 
    PubMed 

    Google Scholar 

  • Xu, X. et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet. 22, 37–43 (1999).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Liu, X. et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl Acad. Sci. USA 104, 12111–12116 (2007).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • McCarthy, A. et al. A mouse model of basal-like breast carcinoma with metaplastic elements. J. Pathol. 211, 389–398 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418–425 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Ludwig, T., Fisher, P., Murty, V. & Efstratiadis, A. Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice. Oncogene 20, 3937–3948 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Szabova, L. et al. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res. 72, 4141–4153 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Perets, R. et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24, 751–765 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Levanon, K., Crum, C. & Drapkin, R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol. 26, 5284–5293 (2008).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Iyer, S. et al. Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy. Cancer Discov. 11, 384–407 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Skoulidis, F. et al. Germline Brca2 heterozygosity promotes KrasG12D-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 18, 499–509 (2010).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Rowley, M. et al. Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology 140, 1303–1313 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Shakya, R. et al. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science 334, 525–528 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Drost, R. et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 20, 797–809 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Drost, R. et al. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. J. Clin. Invest. 126, 2903–2918 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Chen, J. et al. 53BP1 loss rescues embryonic lethality but not genomic instability of BRCA1 total knockout mice. Cell Death Differ. 27, 2552–2567 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Nacson, J. et al. BRCA1 mutational complementation induces synthetic viability. Mol. Cell 78, 951–959 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Park, D. et al. Ablation of the Brca1–Palb2 interaction phenocopies Fanconi anemia in mice. Cancer Res. 80, 4172–4184 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Pulver, E. M. et al. A BRCA1 coiled-coil domain variant disrupting PALB2 interaction promotes the development of mammary tumors and confers a targetable defect in homologous recombination repair. Cancer Res. 81, 6171–6182 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Krais, J. J. et al. RNF168-mediated localization of BARD1 recruits the BRCA1–PALB2 complex to DNA damage. Nat. Commun. 12, 5016 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hartford, S. A. et al. Interaction with PALB2 is essential for maintenance of genomic integrity by BRCA2. PLoS Genet. 12, e1006236 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lim, P. X., Zaman, M., Feng, W. & Jasin, M. BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair. Mol. Cell 84, 447–462 (2024).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Atanassov, B. S., Barrett, J. C. & Davis, B. J. Homozygous germ line mutation in exon 27 of murine Brca2 disrupts the Fancd2–Brca2 pathway in the homologous recombination-mediated DNA interstrand cross-links’ repair but does not affect meiosis. Genes Chromosomes Cancer 44, 429–437 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Pathania, S. et al. BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat. Commun. 5, 5496 (2014).

    Article 
    PubMed 

    Google Scholar 

  • Konishi, H. et al. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc. Natl Acad. Sci. USA 108, 17773–17778 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sedic, M. et al. Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nat. Commun. 6, 7505 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Zong, D. et al. BRCA1 haploinsufficiency is masked by RNF168-mediated chromatin ubiquitylation. Mol. Cell 73, 1267–1281 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Li, C. M. et al. Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer. Nat. Genet. 56, 2763–2775 (2024).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kumar, P. et al. Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution. PLoS Genet. 8, e1003027 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Annunziato, S. et al. Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer. Nat. Commun. 10, 397 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Liu, H. et al. Identifying and targeting sporadic oncogenic genetic aberrations in mouse models of triple-negative breast cancer. Cancer Discov. 8, 354–369 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Menghi, F. et al. The tandem duplicator phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations. Cancer Cell 34, 197–210 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Molyneux, G. et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7, 403–417 (2010).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Sau, A. et al. Persistent activation of NF-κB in BRCA1-deficient mammary progenitors drives aberrant proliferation and accumulation of DNA damage. Cell Stem Cell 19, 52–65 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Bach, K. et al. Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors. Nat. Commun. 12, 1502 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ciwinska, M. et al. Mechanisms that clear mutations drive field cancerization in mammary tissue. Nature 633, 198–206 (2024).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rottenberg, S. et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl Acad. Sci. USA 104, 12117–12122 (2007).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zander, S. A. et al. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res. 70, 1700–1710 (2010).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Pajic, M. et al. Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. Cell Cycle 9, 3780–3791 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Pajic, M. et al. Selected alkylating agents can overcome drug tolerance of G0-like tumor cells and eradicate BRCA1-deficient mammary tumors in mice. Clin. Cancer Res. 23, 7020–7033 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Evers, B. et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin. Cancer Res. 16, 99–108 (2010).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Planells-Cases, R. et al. Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs. EMBO J. 34, 2993–3008 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Widmer, C. A. et al. Loss of the volume-regulated anion channel components LRRC8A and LRRC8D limits platinum drug efficacy. Cancer Res. Commun. 2, 1266–1281 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105, 17079–17084 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hay, T. et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res. 69, 3850–3855 (2009).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Jaspers, J. E. et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 3, 68–81 (2013).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Xu, G. et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature 521, 541–544 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Barazas, M. et al. The CST complex mediates end protection at double-strand breaks and promotes PARP inhibitor sensitivity in BRCA1-deficient cells. Cell Rep. 23, 2107–2118 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ter Brugge, P. et al. Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer. J. Natl Cancer Inst. 108, djw148 (2016).

    Article 

    Google Scholar 

  • Gogola, E. et al. Selective Loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality. Cancer Cell 33, 1078–1093 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Paes Dias, M. et al. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. Mol. Cell 81, 4692–4708 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Barazas, M. et al. Radiosensitivity is an acquired vulnerability of PARPi-resistant BRCA1-deficient tumors. Cancer Res. 79, 452–460 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Juvekar, A. et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2, 1048–1063 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ding, L. et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 25, 2972–2980 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Pantelidou, C. et al. PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 9, 722–737 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Wang, Q. et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat. Commun. 13, 3022 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zatreanu, D. et al. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nat. Commun. 12, 3636 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zhou, J. et al. A first-in-class polymerase θ inhibitor selectively targets homologous-recombination-deficient tumors. Nat. Cancer 2, 598–610 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Mateos-Gomez, P. A. et al. Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination. Nature 518, 254–257 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ceccaldi, R. et al. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature 518, 258–262 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Krais, J. J. et al. Genetic separation of Brca1 functions reveal mutation-dependent Polθ vulnerabilities. Nat. Commun. 14, 7714 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • DuPage, M. & Jacks, T. Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr. Opin. Immunol. 25, 192–199 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Nolan, E. et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci. Transl. Med. 9, eaal4922 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rebbeck, T. R. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346, 1616–1622 (2002).

    Article 
    PubMed 

    Google Scholar 

  • Poole, A. J. et al. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314, 1467–1470 (2006).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Nolan, E. et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat. Med. 22, 933–939 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Sigl, V. et al. RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell Res. 26, 761–774 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • van de Ven, M. et al. BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling. J. Pathol. 246, 41–53 (2018).

    Article 
    PubMed 

    Google Scholar 

  • Gorrini, C. et al. Estrogen controls the survival of BRCA1-deficient cells via a PI3K–NRF2-regulated pathway. Proc. Natl Acad. Sci. USA 111, 4472–4477 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Vinayak, S. & Ford, J. M. PARP inhibitors for the treatment and prevention of breast cancer. Curr. Breast Cancer Rep. 2, 190–197 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • To, C. et al. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev. Res. 7, 698–707 (2014).

    Article 
    CAS 

    Google Scholar 

  • van de Ven, M. et al. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice. J. Pathol. 241, 511–521 (2017).

    Article 
    PubMed 

    Google Scholar 

  • Zeng, J. et al. A genetic mosaic mouse model illuminates the pre-malignant progression of basal-like breast cancer. Dis. Model. Mech. 16, dmm050219 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Singh, A. K. & Yu, X. Tissue-specific carcinogens as soil to seed BRCA1/2-mutant hereditary cancers. Trends Cancer 6, 559–568 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kass, E. M., Lim, P. X., Helgadottir, H. R., Moynahan, M. E. & Jasin, M. Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation. Nat. Commun. 7, 13241 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Uijttewaal, E. C. H. et al. CRISPR-StAR enables high-resolution genetic screening in complex in vivo models. Nat. Biotechnol. 43, 1848–1860 (2024).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Yamashita, M. et al. Cell-type specific, inducible and acute degradation of targeted protein in mice by two degron systems. Nat. Commun. 15, 10129 (2024).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Pettitt, S. J. et al. Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov. 10, 1475–1488 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Billing, D. et al. The BRCT domains of the BRCA1 and BARD1 tumor suppressors differentially regulate homology-directed repair and stalled fork protection. Mol. Cell 72, 127–139 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Stratton, M. R. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349, 1505–1510 (1997).

    Article 

    Google Scholar 

  • Lakhani, S. R. et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl Cancer Inst. 90, 1138–1145 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Bhin, J. et al. Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors. Cell Rep. 42, 112538 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Holstege, H. et al. Cross-species comparison of aCGH data from mouse and human BRCA1– and BRCA2-mutated breast cancers. BMC Cancer 10, 455 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

Continue Reading